NEW YORK – Caris Life Sciences on Wednesday priced its

纽约——Caris Life Sciences于周三定价其

previously announced

之前宣布的

initial public offering of 23,529,412 shares of its common stock at a public offering price of $21 per share, for a total of $494.1 million in gross proceeds.

首次公开募股发行23,529,412股普通股，公开发行价为每股21美元，总计获得4.941亿美元的总收益。

The firm also granted the underwriters a 30-day option to purchase up to an additional 3,529,411 shares of its common stock at the IPO price, potentially

该公司还授予承销商一项30天期权，允许其以首次公开募股价格额外购买至多3,529,411股普通股，潜在地。

adding $74.1 million in gross proceeds

增加7410万美元的毛收入

. Shares are expected to begin trading on the Nasdaq Global Select Market on Wednesday under the ticker symbol CAI, while the offering is expected to close on June 20.

预计股票将于周三开始在纳斯达克全球精选市场交易，股票代码为CAI，而此次发行预计将于6月20日结束。

BofA Securities, JP Morgan, and Goldman Sachs are acting as lead bookrunning managers for the offering, joined by additional bookrunning managers Citigroup, TD Cowen, Evercore ISI, and Guggenheim Securities. BTIG and Wolfe-Nomura Alliance are acting as co-managers for the offering.

美银证券、摩根大通和高盛担任此次发行的首席簿记管理人，花旗集团、TD Cowen、Evercore ISI 和古根海姆证券为额外的联席簿记管理人。BTIG 和 Wolfe-Nomura Alliance 担任此次发行的联席管理人。

Caris offers a portfolio of cancer comprehensive molecular profiling tests that use next-generation sequencing, artificial intelligence, and machine learning. It has also created a large-scale, multimodal clinico-genomic database using more than 6.5 million tests run on more than 849,000 cases, it previously said in its IPO registration statement filed with the US Securities and Exchange Commission.  .

Caris提供了一系列使用下一代测序、人工智能和机器学习的癌症综合分子分析测试。该公司还创建了一个大规模、多模式的临床基因组数据库，该数据库基于超过84.9万例病例进行的650多万次测试，正如其在美国证券交易委员会提交的IPO注册声明中所述。

'This convergence of next-generation sequencing, AI and machine-learning technologies, and high-performance computing provides a differentiated platform to develop the latest generation of advanced precision medicine diagnostic solutions for early detection, diagnosis, monitoring, therapy selection, and drug development,' the company said in a statement.

“下一代测序、人工智能和机器学习技术以及高性能计算的结合，为开发最新一代先进的精准医疗诊断解决方案提供了独特的平台，可用于早期检测、诊断、监测、治疗选择和药物开发，”该公司在一份声明中表示。

.

。

The IPO follows a private financing round in April, where Caris

今年4月，Caris公司进行了一轮融资，此次IPO紧随其后。

raised $168 million

筹集了1.68亿美元

to support the expansion of its genomic testing platform.

支持其基因组测试平台的扩展。